ArticlePractical laboratory medicine2025
Molecular diagnosis of visceral leishmaniasis from blood samples using different genetic markers: A simple, sensitive and less invasive diagnostic approach.
Article in Practical laboratory medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Visceral leishmaniasis (VL), or kala-azar, is a deadly disease with high fatality rates if diagnosis and treatment are delayed. Diagnosis is often delayed due to symptoms that mimic other conditions. Sample isolation and diagnostic procedures are labor-intensive and time-consuming. Rapid immunochromatographic tests cannot differentiate active cases from past infections. In the present study we investigated the utility of peripheral blood samples for molecular diagnosis of VL. Whole genomic DNA from the erythrocyte fraction of blood from VL and cutaneous leishmaniasis (CL) suspected patients was used for PCR using multiple markers (k-DNA, ITS-Ⅰ, and 18s rRNA). PCR amplification of k-DNA, ITS-Ⅰ, and 18s rRNA genes yielded positive results in VL symptomatic patients. However, the same PCR approach with peripheral blood samples from CL patients was not significant. Hence, peripheral blood samples can effectively distinguish active VL cases through PCR using multiple markers, offering a less invasive and labor-intensive diagnostic alternative.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.